Cambridge Institute for Medical Research, Wellcome Trust, MRC Building, Addenbrooke's Hospital, Box 139, Hills Road, Cambridge CB2 0XY, UK.
Curr Opin Pharmacol. 2013 Dec;13(6):922-7. doi: 10.1016/j.coph.2013.08.013. Epub 2013 Sep 10.
Incretin peptides (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are secreted from enteroendocrine cells in the intestinal epithelium, and help to coordinate metabolic responses to food ingestion. A number of molecular mechanisms have recently been defined that underlie carbohydrate, lipid and protein sensing in gut endocrine cells. Knockout mice lacking sodium glucose tranporter-1 (SGLT-1) or the short chain fatty acid sensing receptor FFAR2 (GPR43), for example, have highlighted the importance of these molecules in incretin secretion. This review outlines our current understanding of sensory pathways in incretin secreting cells and highlights the therapeutic potential of targeting them for the development of novel therapies for obesity and diabetes.
肠内分泌细胞从肠道上皮细胞分泌肠降血糖素(GLP-1 和葡萄糖依赖性胰岛素释放多肽(GIP)),帮助协调对食物摄入的代谢反应。最近已经确定了一些分子机制,这些机制是肠道内分泌细胞中碳水化合物、脂质和蛋白质感应的基础。例如,缺乏钠葡萄糖转运蛋白-1(SGLT-1)或短链脂肪酸感应受体 FFAR2(GPR43)的基因敲除小鼠,强调了这些分子在肠降血糖素分泌中的重要性。这篇综述概述了我们对肠降血糖素分泌细胞中感觉途径的理解,并强调了针对这些途径开发肥胖和糖尿病新型治疗方法的治疗潜力。